Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Cuenca López, María D ^a   Montero, Juan C ^b   Morales, Jorge C ^a   Prat, Aleix ^c   Pandiella, Atanasio ^b   Ocana, Alberto ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b CSIC   (Spain)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

AR (Androgen Receptor); EGFR PDFGR ; Erk1 2; Kinase Inhibitors; PI3K mTor; TNBC (triple negative breast cancer); Tyrosine Kinase Receptor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; DACTOLISIB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TYROSINE KINASE RECEPTOR; ANILIDE; AR PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; NITRILE; TARGET OF RAPAMYCIN KINASE; TOLUENESULFONIC ACID DERIVATIVE;

ANDROGEN RECEPTOR GENE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR RECOGNITION; MONOTHERAPY; RECEPTOR GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRIPLE NEGATIVE BREAST CANCER; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANILIDES; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; NITRILES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN; TOR SERINE-THREONINE KINASES; TOSYL COMPOUNDS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84899941391     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-302     Document Type: Article

References (30)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434. 10.1158/1078-0432.CCR-06-3045, 17671126.
4. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med 2002, 346:340-352. 10.1056/NEJMra000471, 11821512.
5. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003, 348:2431-2442. 10.1056/NEJMra023246, 12802030.
6. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003, 120:725-731. 10.1309/42F00D0DJD0J5EDT, 14608899.
7. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, Henshall SM, Birrell SN, Coetzee GA, Sutherland RL, Butler LM, Tilley WD. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009, 69:6131-6140.
8. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, Carroll JS. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J 2011, 30:3019-3027. 10.1038/emboj.2011.216, 3160190, 21701558.
9. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767. 10.1172/JCI45014, 3127435, 21633166.
10. Hickey TE, Robinson JL, Carroll JS, Tilley WD. Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?. Mol Endocrinol 2012, 26:1252-1267. 10.1210/me.2012-1107, 3404296, 22745190.
11. Kotsopoulos J, Narod SA. Androgens and breast cancer. Steroids 2012, 77:1-9. 10.1016/j.steroids.2011.10.002, 22015396.
12. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004, 6:517-527. 10.1016/j.ccr.2004.09.031, 15542435.
13. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Shirley Liu X, Brown M. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011, 20:119-131. 10.1016/j.ccr.2011.05.026, 3180861, 21741601.
14. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011, 19:575-586. 10.1016/j.ccr.2011.04.008, 3142785, 21575859.
15. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, Sawyers CL. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 2007, 104:5563-5568. 10.1073/pnas.0609139104, 1838515, 17372210.
16. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009, 15:2472-2478. 10.1158/1078-0432.CCR-08-1763, 19276248.
17. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.
18. Hochgrafe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ, Daly RJ. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res 2010, 70:9391-9401. 10.1158/0008-5472.CAN-10-0911, 20861192.
19. Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schiff R, Bentires-Alj M, Elledge SJ, Westbrook TF. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 2011, 144:703-718. 10.1016/j.cell.2011.02.003, 21376233.
20. Montero JC, Seoane S, Ocana A, Pandiella A. P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. Oncogene 2011, 30:1059-1071. 10.1038/onc.2010.489, 21042280.
21. Diaz-Rodriguez E, Cabrera N, Esparis-Ogando A, Montero JC, Pandiella A. Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms. Eur J Neurosci 1999, 11:1421-1430. 10.1046/j.1460-9568.1999.00552.x, 10103137.
22. Yuste L, Montero JC, Esparis-Ogando A, Pandiella A. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res 2005, 65:6801-6810. 10.1158/0008-5472.CAN-04-4023, 16061662.
23. Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Earp HS. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 2005, 11:1704-1712. 10.1158/1078-0432.CCR-04-1158, 15755991.
24. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994, 54:5474-5478.
25. Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL, DeVere White RW, Ghosh PM. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res 2011, 17:6218-6228. 10.1158/1078-0432.CCR-11-1548, 3186857, 21844010.
26. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010, 21:488-492. 10.1093/annonc/mdp510, 19887463.
27. Montero JC, Esparis-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, Ocana A, Pandiella A. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene 2014, 33:148-156. 10.1038/onc.2012.572, 23246963.
28. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318:287-290. 10.1126/science.1142946, 17872411.
29. Naderi A, Chia K, Liu J. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res 2011, 13:R36. 10.1186/bcr2858, 3219199, 21457548.
30. Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer. [http://www.clinicaltrial.gov/ct2/show/NCT00755885?term=abiraterone+and+breast&rank=2].